VEKTIS Study: Conclusions

  • The VEKTIS study demonstrated that 4-month treatment with CsA CE 0.1% in patients with active severe VKC resulted in significant improvement in CFS scores, VKC symptoms, and quality of life and reduced use of rescue medication vs. vehicle alone1,2
    • – This improvement was maintained over the 12-month course of the study2
  • Safety analyses suggested a favorable tolerability profile for CsA CE1–3
    • – Safety profiles for the QID and BID regimens were similar

1. Bremond-Gignac D et al. Presented at the 2017 Annual Meeting of the American Academy of Ophthalmology; Nov. 11–14, 2017; New Orleans, Louisiana. 2. Leonardi A et al. Presented at 8th EU Cornea Congress; October 6–7, 2017; Lisbon, Portugal 3. Leonardi A et al. Presented at 8th EU Cornea Congress; October 6–7, 2017; Lisbon, Portugal.